Week In Review: Akeso Out-Licenses PD-1/VEGF To Summit In $5 Billion Pact

In a blockbuster agreement, Guangzhou’s Akeso out-licensed ex-China rights to its bispecific PD-1/VEGF candidate in a deal worth up to $5 billion. Summit Therapeutics will pay $500 million upfront and up to $4.5 billion in milestones.